natgillin/translations-raw huggingface dataset:
DepoCyte skal anvendes så snart som muligt efter at være blevet åbnet første gang og skal normalt anvendes i løbet af 4 timer (opbevares ved 18 – 22 ºC).
DepoCyte should be used as soon as possible after first opening, and should normally be used within 4 hours (stored at 18-22ºC).
Depolariserende muskelafslappende lægemidler
Depolarising muscle relaxant acting medicinal products
Deponering i lungen af inhaleret aclidiniumbromid via Genuair-inhalatoren var i gennemsnit cirka 30 % af den afmålte dosis.
Whole lung deposition of inhaled aclidinium via Genuair averaged approximately 30% of the metered dose.
depot)/600 mg én gang dagligt]
release)/600 mg once daily]
Depot- formulering af exenatid 2 mg
Prolonged- release exenatide 2 mg
Depotform af medroxyprogesteronacetat
Medroxyprogesterone acetate depot
Depotformulering af exenatid bør ikke anvendes under graviditet og anvendelse af insulin anbefales.
Prolonged-release exenatide should not be used during pregnancy and the use of insulin is recommended.
Depotformulering af exenatid har ikke vist nogen uønskede effekter på lipidparametrene.
Prolonged-release exenatide has shown no adverse effects on lipid parameters.
Depotformulering af exenatid medførte en større ændring i HbA1c sammenlignet med insulin glargin.
Prolonged-release exenatide demonstrated a superior change in HbA1c compared to insulin glargine.
Depotformulering af exenatid skal seponeres mindst 3 måneder inden en planlagt graviditet.
Prolonged-release exenatide should be discontinued at least 3 months before a planned pregnancy.
Depotinjektionsvæske
Prolonged-release suspension for injection
Depotinjektionsvæske, suspension
Prolonged release suspension for injection
Depotinjektionsvæske, suspension 1 fyldt injektionssprøjte
Prolonged release suspension for injection 1 pre-filled syringe
Depotinjektionsvæske, suspension Dag 1
Prolonged release suspension for injection Day 1
Depotinjektionsvæske, suspension Dag 8
Prolonged release suspension for injection Day 8
Depotinjektionsvæske, suspension Pakning til behandlingsstart
Prolonged release suspension for injection Treatment initiation pack
Depotplaster
Transdermal patch
Depotplaster.
Transdermal patch.
Depotplastre
Transdermal patches
Depotplastre.
Transdermal patch.
Depotplastrene er rektangulære med afrundede hjørner, plastre, cirka 2,5 cm x 1,8 cm Rivastigmine 3M Health Care Ltd.
The transdermal patches are rectangular with rounded corners, approximately 2.5 cm by 1.8 cm (Rivastigmine 3M Health Care Ltd.
Depotplastret kan dog løsnes delvist.
However, the transdermal patch may become partially unstuck.
Depotplastret kan påvirkes af direkte sollys, eller hvis det udsættes for sollamper.
The transdermal patch may be affected by direct sunlight or exposure to sunlamps.
Depotplastret må ikke klippes i mindre stykker.
Do not cut the transdermal patch into smaller pieces.
Depottablet
Prolonged release tablet
Depottablet
Prolonged-release tablet
Depottablet
tablet
Depottablet Intuniv 1 mg tablet
Prolonged-release tablet Intuniv 1 mg tablet
Depottablet.
Prolonged-release tablet
Depottabletten bør ikke deles.
The prolonged- release tablet should not be divided.
Depottabletten bør ikke deles.
The prolonged-release tablet should not be divided.
Depottabletter
Prolonged-release tablet
Depottabletter
Prolonged-release tablet.
Depottabletter 20 tabletter
Prolonged-release tablets 20 tablets
Depottabletter er ikke egnede til den 14-dages optrapningsperiode for nye patienter i nevirapinbehandling.
Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine.
Depottabletter Sifrol 0,26 mg depottabletter
Prolonged-release tablet SIFROL 0.26 mg prolonged-release tablets
Depottabletterne bør synkes hele med vand og må ikke tygges, deles eller knuses.
The tablets should be swallowed whole with water, and must not be chewed, divided or crushed.
Depottabletterne er ca.
The prolonged-release tablets are about 9.3 x
Depresión medular1 , incluida neutropenia (< 2,0 x 109/l), reticulocitopenia (< 80 x 109/l), macrocitosis2
Bone marrow depression1 including neutropenia (< 2.0 x 109/l), reticulocytopenia (< 80 x 109/l), macrocytosis2
depression
depressio n
Depression
depression.
depression
depression;
Depression
Very Common
depression (følelse af dyb bedrøvelse eller af at være værdiløs)
depression (feelings of deep sadness and unworthiness)
Depression (svær hos 1,6%)3, angst3, abnorme drømme3, søvnløshed3
depression (severe in 1.6%)3, anxiety3, abnormal dreams3, insomnia3
Depression (såsom monoaminooxidasehæmmere eller tricykliske antidepressiva),
depression (such as monoamine oxidase inhibitors or tricyclic antidepressants),
Depression Amnesi Forvirring Søvnløshed Paræstesi Hypæstesi Nervøsitet Tør mund
Depression Amnesia Confusion Insomnia Paraesthesia Hypoaesthesia Nervousness Dry mouth
Depression Angst Konfusion Søvnløshed
Depression Anxiety Confusional state Insomnia
Depression eller aggression (selvom disse bivirkninger er mere sandsynlige hos børn, der får denne lægemiddelkombination i en lavere styrke).
Depression or aggression (although these effects are more likely to occur in children when prescribed this combination of drugs but in a lower strength).
depression eller angst, koncentrationsbesvær, døsighed
feeling depressed or anxious, not being able to concentrate, feeling drowsy
Depression eller problemer, som påvirker dit humør
Depression or problems affecting your mood
Depression eller psykiske problemer.
Depression or mental health problems.
Depression er almindelig (kan forekomme hos op til 1 ud af 10 personer) hos behandlede patienter med multipel sklerose.
Depression is common (may affect up to 1 in 10 people) in treated patients with multiple sclerosis.
Depression er forbundet med en øget risiko for selvmords- tanker, at forvolde skade på sig selv og selvmord (selvmordsrelaterede handlinger).
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events).
Depression er forbundet med en øget risiko for selvmordstanker, at forvolde skade på sig selv og selvmord (selvmordsrelaterede handlinger).
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide- related events).
depression forstyrret eller forringet blodomløb (såsom Raynauds sygdom eller Raynauds syndrom eller cerebral insufficiens)
depression disturbed or poor blood circulation (such as Raynaud’s disease or Raynaud’s syndrome or cerebral insufficiency)
Depression og nedtrykt tilstand
Depression and depressed mood
Depression og nedtrykthed
Depression and depressed mood
Depression sættes i forbindelse med en øget risiko for selvmordstanker, selvpåført skade og selvmord (selvmordsrelaterede hændelser).
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide- related events).
Depression*, angst, søvnløshed*
Depression*, anxiety, insomnia
Depression, abnorm tankevirksomhed, insomnia
Depression, thinking abnormal, insomnia
depression, angst
agitation, depression, anxiety
depression, angst
depression, anxiety
Depression, angst*, emotionel labilitet*, nedsat koncentration, søvnløshed
Depression, anxiety*, emotional lability*, concentration impaired, insomnia
depression, angst, insomni
depression, anxiety, insomnia
Depression, angst, insomni, søvnforstyrrelser, unormale drømme, humørsvingninger
Depression, Anxiety, Insomnia, Sleep disorder, Abnormal dreams, Mood swings
depression, angst, ophidselse
depression, anxiety, agitation
depression, angst, søvnforstyrrelser
depression, anxiety, sleep disorder
depression, angst, søvnforstyrrelser
depression, anxiety, sleep disturbance
depression, angst, søvnløshed
depression, anxiety, insomnia
depression, angst, søvnløshed (insomni), irritabilitet
depression, anxiety, unable to sleep (insomnia), irritability
depression, angst, søvnløshed, søvnforstyrrelser, unormale drømme, humørsvingninger
depression, anxiety, inability to sleep, sleep disorder, abnormal dreams, mood swings
depression, bekymringer (angst) eller humørsvingninger (affektlabilitet)
feeling depressed, worried (anxiety) or having mood swings (affect lability)
depression, desorientering, angst, søvnforstyrrelser, unormale drømme, mareridt, nedsat libido
depression, disorientation, anxiety, sleep disorder, abnormal dreams, nightmare, decreased libido
Depression, emotionel ustabilitet, søvnløshed
Depression, emotional lability, insomnia
Depression, epileptisk anfald.
Depression, epileptic attack.
depression, fjendtlighed eller aggression, angst, søvnløshed, nervøsitet eller irritabilitet;
depression, hostility or aggression, anxiety, insomnia, nervousness or irritability
depression, fjendtlighed eller aggression, angst, søvnløshed, nervøsitet eller irritabilitet;
depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
depression, fjendtlighed eller aggressiv adfærd, angst, søvnløshed, nervøsitet eller irritabilitet
depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
Depression, fjendtlighed/ aggression, angst, insomni, nervøsitet/ irritabilitet
Depression, hostility/ aggression, anxiety,
Depression, fjendtlighed/agg ression, angst, insomni, nervøsitet/ irritabilitet
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritabilit y
Depression, fjendtlighed/aggressi on, angst, insomni, nervøsitet/ irritabilitet
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritabilit y
Depression, fjendtlighed/aggressio n, angst, insomni, nervøsitet/ irritabilitet
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability
Depression, forvirring, humørsvingninger, angst.
Depression, confusion, mood changes, anxiety.
depression, hallucination eller forvirring
depression, hallucination or confusion
Depression, hallucination, forvirring
Depression, hallucination, confusion
depression, hallucinationer, angst, søvnløshed, agitation, konfusion
depression, hallucination, anxiety, insomnia, agitation, confusional state
depression, hukommelsestab
depression, memory loss
Depression, hukommelsestab
Depression; memory loss
Depression, insomni
Depression, insomnia
depression, irritabilitet
depression, irritability
depression, mental svækkelse
depression, mental impairment
Depression, nedsat libido*
Depression, libido decreased
depression, nervøsitet
depression, nervousness,
depression, nervøsitet
severe vision loss5
Depression, problemer med at sove
Depression, problems sleeping
Depression, søvnbesvær, dårlig søvnkvalitet, besvimelse, følelse af at ville besvime, fald, tømmermænd, svaghed, ubehag i benene, øget berøringsfølsomhed, hovedpine efter skader, brændende fornemmelse, abnorme smagsindtryk
Depression, inability to sleep, poor quality sleep, fainting, fainting sensation, fall, hangover, weakness, inability to get legs comfortable, increased sensitivity to touch, headache following injury, burning sensation, abnormal taste sensation
depression, søvnforstyrrelse
depression, sleep disorder
depression, søvnforstyrrelser, desorientering, ængstelse
depression, sleep disorder, disorientation, anxiety
depression, søvnløshed
depression, insomnia
Depression, søvnløshed, angst, emotionel labilitet
Depression, anxiety, emotional lability, insomnia
Depression, søvnløshed, angst, emotionel labilitet
Depression, insomnia, anxiety, emotional lability
Depression, søvnløshed, angst, emotionel labilitet, søvnløshed
Depression, anxiety, emotional lability, insomnia
Depression, søvnløshed, angst, følelsesmæssig ustabilitet*,
Depression, insomnia, anxiety, emotional lability*,
depression, søvnproblemer
depression, difficulty sleeping,
Depression, søvnproblemer
Depression, sleep problems
Depression, udmattelse, træthed, døsighed eller manglende energi, generel utilpashed, vejrtrækningsbesvær i liggende stilling, næseblod
Depression, fatigue, feeling of tiredness, drowsiness, or lack of energy, general feeling of being unwell, difficulty breathing when laying down, nose bleeding
depression, ængstelse
depression, anxiety
Depression.
Depression
depression2, nedtrykthed2, søvnforstyrrelser2, unormale drømme1, 2
depression2, depressed mood2, sleep disorders2, abnormal dreams1, 2
depression; abnorme drømme,
depression; abnormal dreams;
Depression; insomni^
Depression; Insomnia^
depressionsfølelse
feeling depressed,
depressionsfølelse,
feeling depressed,
depressionsfølelse, irritabilitet, besvær med at falde i søvn eller sove igennem, følelse af angst eller nervøsitet, koncentrationsbesvær, humørsvingninger,
feeling depressed, irritability, trouble falling asleep or staying asleep, feeling anxious or nervous, difficulty concentrating, mood swings,
Depressive sygdomme
Depressive disorders
Deprimeret, irritabel eller rastløs.
Feeling depressed, irritable or restless.
der
0.0020
Der
observed.
Der
There
Der afventes yderligere oplysninger om kvalitet, sikkerhed og virkning.
Additional information on quality, safety and efficacy is awaited.
Der anbefales at medicinen anvendes straks efter rekonstitution.
After reconstitution, immediate use is recommended.
Der anbefales at Tamiflu-pulver til oral suspension rekonstitueres af apoteket, før den udleveres til patienten (se pkt.6.6).
It is recommended that Tamiflu powder for oral suspension be constituted by a pharmacist prior to dispensing to the patient (see section 6.6).
Der anbefales derfor at udvise forsigtighed, når der føres motorkøretøj eller betjenes maskiner.
Therefore, caution is recommended when driving or operating machines.
Der anbefales en dosering på 340 mg/m² dagligt til børn med CML i kronisk fase og i accelereret fase (må ikke overskride en total dosering på 800 mg).
The dose of 340 mg/m2 daily is recommended for paediatric patients with chronic phase CML and accelerated phase CML (not to exceed the total dose of 800 mg).
Der anbefales en dosis på 340 mg/m² daglig til børn med Ph+ ALL (totaldosis på 600 mg må ikke overskrides).
The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).
Der anbefales en dosis på 340 mg/m² dagligt til børn med Ph+ ALL (totaldosis på 600 mg må ikke overskrides).
The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).
Der anbefales en initialdosis på 90 µg pr. kg legemsvægt givet som intravenøs bolusinjektion.
The recommended initial dose, administered by intravenous bolus injection, is 90 µg per kg body weight.
Der anbefales en initialdosis på 90 µg pr. kg legemsvægt givet som intravenøs bolusinjektion.
The recommended initial dose, administered by intravenous bolus injection, is 90 g per kg body weight.
Der anbefales en mild sæbe ved kar- eller brusebadning.
A mild soap is recommended when bathing or showering.
Der anbefales en startdosis på 18,5 mg, og den maksimale dosis lurasidon må ikke overstige 74 mg en gang dagligt i kombination med moderate CYP3A4-hæmmere.
A starting dose of 18.5 mg is recommended and the maximum dose of lurasidone should not exceed 74 mg once daily in combination with moderate CYP3A4 inhibitors.
Der anbefales en årlig vaccination med en enkelt dosis Versican Plus Pi.
A single dose of Versican Plus Pi to be given annually.
Der anbefales en årlig vaccination med en enkeltdosisVersican Plus Pi.
A single dose of Versican Plus Pi to be given annually.
Der anbefales en årlig vaccination med Versican Plus L4.
A single dose of Versican Plus L4 to be given annually.
Der anbefales en årlig vaccination med Versican Plus Pi/L4.
Re-vaccination scheme: A single dose of Versican Plus Pi/L4 to be given annually.
Der anbefales hyppig monitorering for bivirkninger og toksicitet relateret til antiretrovirale midler, der er CYP3A4 substrater under samtidig indtagelse med posaconazol.
to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole.
Der anbefales hyppig monitorering for bivirkninger og toksicitet relateret til antiretrovirale midler, der er CYP3A4-substrater, ved administration samtidig med posaconazol.
Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co- administration with posaconazole.
Der anbefales hyppigere monitorering af hæmatologi-parametre og kliniske tegn og symptomer på Jakavi- relaterede bivirkninger for patienter med baseline hæmoglobin under 10,0 g/dl.
More frequent monitoring of haematology parameters and of clinical signs and symptoms of Jakavi-related adverse drug reactions is recommended for patients with baseline haemoglobin below 10.0 g/dl.
Der anbefales ikke aldersbaseret dosisjustering.
No dose adjustment is recommended based on age.
Der anbefales ikke dosisjustering af temsirolimus hos patienter med nyreinsufficiens.
No dose adjustment of temsirolimus is recommended in patients with renal impairment.
Der anbefales ikke dosisjustering for patienter med nedsat nyrefunktion (se pkt.
No dose adjustment is recommended for patients with renal impairment (see section 5.2).
Der anbefales ikke dosisjustering ved mildt til moderat nedsat nyrefunktion (kreatininclearance på > 30 ml/minut) (se pkt.
No dose adjustment is recommended for mild to moderate renal impairment (creatinine clearance >30 ml/min) (see section 5.2).
Der anbefales ingen
No particular dose adjustment is
Der anbefales ingen dosisjustering af temsirolimus hos patienter med fremskreden renalcellekarcinom (RCC) og let til moderat leverinsufficiens.
No dose adjustment of temsirolimus is recommended for patients with advanced renal cell carcinoma (RCC) and mild to moderate hepatic impairment.
Der anbefales ingen dosisjustering alene på baggrund af alderen.
No dose adjustment is recommended based on age alone.
Der anbefales ingen dosisjustering til patienter med let nedsat leverfunktion.
No dose adjustment is recommended for patients with mild hepatic impairment.
Der anbefales ingen dosisjustering, men forsigtighed tilrådes hos patienter med moderat nedsat leverfunktion.
No dose adjustment is suggested but caution is adviced in patients with moderate hepatic impairment.
Der anbefales ingen dosisjustering.
No clinical data available for the
Der anbefales ingen dosismodifikationer for alvorlig lymfopeni på grund af virkemekanismerne for MabCampath.
There are no dose modifications recommended for severe lymphopenia given the mechanism of action of MabCampath.
Der anbefales ingen justering af den sædvanlige dosis hos patienter med let nedsat nyrefunktion (se pkt.
No adjustment of the standard dose is recommended in patients with mild renal impairment (see section 5.2).
Der anbefales ingen yderligere dosisjusteringer hos ældre mennesker.
No additional dose adjustments are recommended for older people.
Der anbefales monitorering af INR (international normaliseret ratio).
No dose adjustment is recommended.
Der anbefales oftalmologisk undersøgelse med regelmæssige mellemrum eller hvis der fremkommer synsabnormaliteter.
Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.
Der anbefales også at monitorere patientens hiv- behandling.
An interaction is possible.
Der anbefales periodisk kontrol af serum-kalium og serum-kreatinin, hvis Ifirmasta anvendes til patienter med nedsat nyrefunktion.
When Ifirmasta is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Der anbefales periodisk kontrol af serum-kalium- og serum-kreatinin, hvis irbesartan anvendes til patienter med nedsat nyrefunktion.
When irbesartan is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Der anbefales én inhalation dagligt, helst på samme klokkeslæt hver dag.
The recommended dose is one inhalation per day at the same time each day.
Der anvendes en ske til at blande indholdet af brevene med 30 ml væske.
A spoon is used to mix the content of the sachets with 30 ml of the beverage.
Der anvendes en ske til at blande indholdet af det pågældende antal breve (4 eller 5 breve afhængigt at spædbarnets vægt) med 10 ml tilberedt modermælkserstatning i medicinkoppen eller den lille beholder.
A spoon is used to mix the content of the appropriate number of sachets (4 or 5 sachets depending on infant weight) with 10 ml of prepared liquid infant formula in the medicine cup or small container.
Der anvendes samme dosis og hyppighed som for indgivelse af olanzapin filmovertrukne tabletter.
It has the same dosage and frequency of administration as olanzapine film- coated tablets.
Der anvendes sædvanligvis, når andre lægemidler eller behandlinger har slået fejl hos voksne med følgende sygdomme: reumatoid arthritis (leddegigt, en sygdom i immunsystemet, der medfører inflammation (betændelsesreaktion) i leddene).
It is usually used when other medicines or treatments have failed, in adults with the following diseases: rheumatoid arthritis (an immune-system disease causing inflammation of the joints).
Der anvendes til behandling af voksne med langvarig (kronisk) hepatitis C (en smitsom sygdom, der angriber leveren og forårsages af hepatitis C-virus).
It is used to treat chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus) in adults.
Der anvendes ét Evra-plaster pr. uge i tre uger, og den fjerde uge er plasterfri.
Evra is used as one patch per week for three weeks, followed by a fourth week, which is patch-free.
Der anvendtes en afskæring på > 2 %
A cut-off of >2% was applied
Der behandles én gang med veterinærlægemidlet.
A single dose of the veterinary medicinal product should be administered.
Der behøves ingen dosisjustering for personer over 65 år (se pkt.
No dose adjustment is recommended for individuals older than 65 years of age (see section 5.2).
Der behøves ingen dosisjustering hos ældre.
No dose adjustment is needed in elderly patients.
Der behøves intet ekstra præventionsmiddel.
No additional contraceptive is needed.
Der bemærkedes ingen karcinogenecitet ved doser på 400 mg/kg/dag hos mus og 600 mg/kg/dag hos rotter, svarende til ekspositioner på henholdsvis  39 og 168 gange den forventede humane eksposition, hvilket antyder et ikke-signifikant karcinogent potentiale af stavudin ved klinisk anvendelse.
No carcinogenicity was noted at doses of 400 mg/kg/day in mice and 600 mg/kg/day in rats, corresponding to exposures ~ 39 and 168 times the expected human exposure, respectively, suggesting an insignificant carcinogenic potential of stavudine in clinical therapy.
Der bemærkes desuden et fald i aspartattransaminase.
A decrease in aspartate transaminase is also noticed.
Der benyttes følgende frekvenser:
The frequency categories used are:
Der benyttes følgende hyppigheder:
The frequency categories used are:
Der benyttes følgende hyppigheder: meget almindelig (1/10), almindelig (1/100 til < 1/10), ikke almindelig (1/1.000 til <1/100), sjælden (1/10.000 til <1/1.000), meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000), not known (cannot be estimated from available data).
Der benyttes følgende hyppigheder: meget almindelig (1/10), almindelig (1/100 til <1/10), ikke almindelig (1/1.000 til <1/100), sjælden (1/10.000 til <1/1.000), meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000), not known (cannot be estimated from available data).
Der blev administreret flere doser af pirfenidon op til en dosis på 4.806 mg/dag i form af seks kapsler 267 mg tre gange dagligt til raske frivillige forsøgspersoner over en 12-dages dosistitreringsperiode.
Multiple doses of pirfenidone up to a dose of 4,806 mg/day were administered as six 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation period.
Der blev anvendt doser på op til 20 kapsler dagligt under udviklingen og afprøvningen af lægemidlet.
Doses of up to 20 capsules a day were used during the development and testing of the medicine.